期刊文献+

厄贝沙坦/氢氯噻嗪治疗老年高血压的疗效及安全性观察 被引量:1

The efficacy and safety of Irbesartan/Hydrochlorothiazide treatment of hypertension in the elderly
下载PDF
导出
摘要 目的探讨厄贝沙坦/氢氯噻嗪复方片(商品名:安博诺)治疗老年高血压的疗效及安全性。方法对60例轻中度老年高血压患者应用安博诺治疗24周,观察其降压疗效和不良反应。结果安博诺服药4周、8周、12周、24周后患者SBP和DBP显著下降(P<0.01),降压总有效率达90.0%,血压达标率85.0%;治疗前后电解质、尿酸、肾功能、血糖、血脂比较差异无统计学意义(P>0.05),无明显不良反应。结论安博诺治疗老年高血压安全、有效。 OBJECYIVE To investigate the efficacy and safety of Irbesartan/Hydrochlorothiazide compound tablets (brand name:Ember's) in treatment of hypertension in the elderly.METHODS 60 patients with mild to moderate hypertensive patients with senile Ember's treatment for 24 weeks, to observe its antihypertensive effica cy and adverse reactions. RESULTS Compared with before treatment, SBPand DBP had fallen significantly in 4, 8, 12 and 24 weeks(P 〈 0.05). Ember's buck total effective rate was 90.0 %, blood pressure compliance rate was 85.0 %. There were no changes in electrolyte, uric acid, renal function, blood sugar and lipid ( P 〉 0.05). There was no obvious adverse reactions. CONCLUSION Ember's is safe and effective in treatment of senile hyperten sion .
作者 王珊波
出处 《海峡药学》 2012年第2期76-77,共2页 Strait Pharmaceutical Journal
关键词 厄贝沙坦 氢氯噻嗪 安博诺 高血压 Irbesartan Hydrochlorothiazide Ember's Hypertension
  • 相关文献

参考文献6

二级参考文献11

  • 1Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2003,42:239-246.
  • 2Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,29;356:366-372.
  • 3Howe P, Phillips P, Saini R, et al.The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999,21:1373-1396.
  • 4中国高血压防治指南起草委员会.1999中国高血压防治指南[J].高血压杂志,2000,8:94-112.
  • 5European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens,2003,21:1011-1053.
  • 6Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998,351:1755-1762.
  • 7Mancia G,Giannattasio C,Grassi G.Current antihypertensive treat2 ment:Can we do better[J].Am J Hypertens,1999,12(13):131-138.
  • 8戴俊明,卫志华,张蓓燕,沈贻谔,傅华.社区高血压病人的药物利用与依从性关系分析[J].高血压杂志,2001,9(1):65-67. 被引量:373
  • 9杜文民,王永铭,陈斌艳,范维琥,耿晓芳.社区高血压人群的血压控制率、药物不良反应及其影响因素[J].中国临床药理学杂志,2001,17(6):434-439. 被引量:33
  • 10戴俊明,傅华,沈贻谔,傅东波,李洋,史方.社区高血压病人个体特征与药物治疗依从性关系研究[J].中国公共卫生,2002,18(1):15-16. 被引量:39

共引文献4079

同被引文献4

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部